Status
Conditions
About
Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
- Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.
Loading...
Central trial contact
Camille WICKER, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal